Fortrea Inc. (FTRE)
Fortrea Inc. (FTRE) Stock Price, Analysis & Data
| Bid | 13.92 |
| Market Cap | 1.74B |
| Revenue (ttm) | 2.68B |
| Net Income (ttm) | -85.2M |
| Beta | 1.97 |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | n/a |
| Forward PE | 16.09 |
| P/B (ttm) | 3.33 |
| P/S (ttm) | 0.65 |
| Earnings Date | Nov 5, 2026 |
| Ask | 23.56 |
| Volume | 1,628,234 |
| Avg. Volume (20D) | 1,435,838 |
| Open | 19.33 |
| Previous Close | 19.52 |
| Day's Range | 18.30 - 19.35 |
| 52-Week Range | 7.10 - 21.39 |
| Analyst | Buy |
| Price Target | 22 (20.02%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical deve...
Financial Performance
In 2025, Fortrea's revenue was 2.72B, an increase of 1% compared to the previous year's 2.7B. Earnings were -986.2M, an increase of 200.21%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for FTRE stock is "Buy". The 12-month stock price forecast is 22, which is upside of 20.02% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
